Health Equity and Risk Communication in Pharmacogenomics
Health Equity and Risk Communication in Pharmacogenomics
批准号:
10681471
负责人:
Loren Saulsberry
金额:
$16.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-09-15 至 2025-08-31
关键词:
Active LearningAdoptionAutomobile DrivingAwardBeliefCaringCharacteristicsChicagoChronic DiseaseClinicalClinical TrialsCommunicationData SetDecision MakingDevelopmentDevelopment PlansDoctor of PhilosophyDrug PrescriptionsDrug usageEducational workshopEmpirical ResearchEnsureEthnic OriginExpenditureExposure toFocus GroupsFoundationsFutureGeneticGenomic medicineGenomicsGoalsGrantGuidelinesHealthHealth PersonnelHealth PolicyHealth SciencesHealthcareIncidenceInstitutionInsuranceInterventionInterviewJournalsK-Series Research Career ProgramsKnowledgeLaboratoriesLeadershipMeasuresMedicalMedicineMentorsMentorshipMethodsMinorityMinority GroupsModelingOutcomePatient CarePatient riskPatient-Centered CarePatientsPharmaceutical PreparationsPharmacogenomicsPharmacotherapyPhysiciansPopulationPopulation HeterogeneityPopulation SciencesPreparationProcessProviderRaceRandomizedResearchResearch PersonnelResourcesRiskScientistSeriesStructureSurveysTechnologyTestingTimeTrainingTranslational ResearchUncertaintyUniversitiesWorkWritingcare deliverycareercareer developmentclinical implementationclinical practicecomorbiditydesigndissemination scienceethnic disparityethnic diversityevidence baseexpectationexperienceexperimental studygenome scienceshealth care disparityhealth care service utilizationhealth disparityhealth equityhealth equity promotionhealth literacyimplementation researchimplementation scienceimplementation studyimprove minority healthimprovedmeetingsminority patientpatient orientedpatient populationpatient responsepatient variabilitypatient-clinician communicationprecision medicinepreferenceprofessorprogramsresearch to practiceresponseside effectskills
中文摘要
项目摘要/摘要
该指导临床科学家研究职业发展奖(K08)的目的是提供博士。
Loren Saulsberry,有指导的培训经验,旨在引导您在
基因组医学。索尔斯伯里博士拥有卫生政策博士学位。她目前是一名助理教授
芝加哥大学健康科学系。她的长期职业目标是领导一项研究
评估和指导药物基因组学(PGx)在临床实践中的实施
促进基因组医学健康公平的方式。这项提议的工作利用了她培养出来的技能
通过先前的培训和研究,并将构成成功的R01提案的基础。职业生涯
发展计划包括药物基因组学的教学和体验式学习;发展研究技能
在实施科学方面;获得领导技能,指导跨学科、实施研究
以及通过一系列目标最大限度地促进职业发展。索尔斯贝里博士也将出席
研讨会,期刊俱乐部,实验室和研究会议,赠款撰写讲习班,并在国家
会议,这些会议都将提供发展和加强技能的更多机会。导师团队
因为拟议的跨学科项目涵盖了PGX研究的整个翻译周期,以确保培训
对独立性的准备是全面的,包含了从
从研究到实践。拟议的研究建立在索尔斯伯里博士之前在健康差异和慢性疾病方面的工作基础上。
疾病;它调查对PGx实施至关重要的沟通过程,为
未来的研究将演变出向有健康差距风险的患者提供PGx护理的方法。目标1
用循证的PGx指南调查处方药使用中的种族差异
并基于全国代表性评估了PGx检测对少数族裔人群的潜在影响
关于卫生保健利用的数据集。目标2确定患者-提供者对PGx风险的看法
通过访谈/焦点小组进行沟通,并检查患者风险之间的种族差异
通信首选项。目标3使用调查实验来评估PGx风险信息的影响
关于不同种族患者对PGx临床使用的信念和偏好。这项建议回应了紧急情况
需要找到根据不同种族的期望和需求调整PGx实施的方法
为了不扩大健康差距,必须确保所有人口的健康状况。K08奖将使索尔斯伯里博士过渡到
独立的基因组医学生涯,专注于设计和调整PGx实现,即
以少数族裔为中心。
英文摘要
PROJECT SUMMARY/ABSTRACT
The purpose of this Mentored Clinical Scientist Research Career Development Award (K08) is to provide Dr.
Loren Saulsberry with a mentored training experience designed to lead to an independent academic career in
genomic medicine. Dr. Saulsberry has a PhD in Health Policy. She is currently an Assistant Professor in the
Department of Health Sciences at The University of Chicago. Her long-term career goal is to lead a research
program that evaluates and guides the implementation of pharmacogenomics (PGx) into clinical practice in a
manner that advances health equity in genomic medicine. The proposed work leverages skills she developed
through prior training and research and will form the basis for a successful R01 proposal. The career
development plan includes didactic and experiential learning in pharmacogenomics; developing research skills
in implementation science; acquiring leadership skills for directing interdisciplinary, implementation research
teams; and maximizing professional development through a series of objectives. Dr. Saulsberry will also attend
seminars, journal clubs, laboratory and research meetings, grant-writing workshops, and present at national
meetings, which will all provide additional opportunities to develop and strengthen skills. The mentorship team
for the proposed interdisciplinary project covers the full translational cycle of PGx research to ensure training
and preparation for independence is comprehensive, incorporating knowledge of each stage of translation from
research to practice. The proposed studies build on Dr. Saulsberry's prior work in health disparities and chronic
illness; it investigates communication processes essential to PGx implementation, providing a foundation for
future studies that evolve approaches for delivering PGx care to patients at risk for health disparities. Aim 1
investigates the inter-ethnic disparities in the use of prescription drugs with evidence-based PGx guidelines
and assesses the potential impact of PGx testing on minority populations based on a nationally representative
dataset on health care utilization. Aim 2 determines the views of patient-provider pairs on PGx risk
communication through interviews/focus groups and examines inter-ethnic variation between patients' risk
communication preferences. Aim 3 uses a survey experiment to evaluate the influence of PGx risk information
on inter-ethnic patient beliefs and preferences for the clinical use of PGx. This proposal responds to the urgent
need to discover methods of tailoring PGx implementation to the expectations and needs of ethnically diverse
populations so as to not widen health disparities. The K08 award will lead to Dr. Saulsberry's transition to an
independent career in genomic medicine focused on designing and adapting PGx implementation that is
minority-centered.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1111/1475-6773.14102
发表时间:
2023-08
期刊:
HEALTH SERVICES RESEARCH
影响因子:
3.4
作者:
[Saulsberry, Loren, Bhargava, Ankur, Zeng, Sharon, Gibbons, Jason B., Brannan, Cody, Lauderdale, Diane S., Gibbons, Robert D.]
通讯作者:
Gibbons, Robert D.
Health Equity and Risk Communication in Pharmacogenomics
-
批准号:10264062
-
项目类别:
-
资助金额:$16.73万
-
财政年份:2020
-
负责人:Loren Saulsberry
-
依托单位:
Health Equity and Risk Communication in Pharmacogenomics
-
批准号:10474443
-
项目类别:
-
资助金额:$16.73万
-
财政年份:2020
-
负责人:Loren Saulsberry
-
依托单位:
海外基金